rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Thomas Patrick Kelly

Chief Financial Officer

Company insider

Files Form 4 as: Chief Financial Officer, Xenon Pharmaceuticals; Chief Financial Officer, Deciphera Pharmaceuticals; CFO & SVP Finance & Corp. Dev,, Critical Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
117
Buys
2
Sells
27
Bought
$568K
Sold
$6.5M
Companies
3
Companies where not an officer
0
First trade
20 Aug 2007
Last trade
15 Oct 2026
Last filed
16 Oct 2026

Companies traded

Where they are an officer
XENE Xenon PharmaceuticalsOfficer · Biotechnology · last 15 Oct 20261 buy · 0 sells
Deciphera PharmaceuticalsOfficer · last 11 Jun 20240 buys · 27 sells
Critical TherapeuticsOfficer · last 14 Feb 20081 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
01Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
15 Oct 2026filed 16 Oct 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Code M—7,500filing
15 Oct 2026filed 16 Oct 2026XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code M—7,500 at $0.00filing
30 Sep 2026filed 1 Oct 2026XENE Xenon PharmaceuticalsBiotechnologySEC FORM 4 Bought$560K15,000 at $37.32filing
15 Oct 2025filed 17 Oct 2025XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—225,000 at $0.00filing
15 Oct 2025filed 17 Oct 2025XENE Xenon Pharmaceuticalsoption or derivative · BiotechnologySEC FORM 4 Code A—30,000 at $0.00filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—85,456filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—5,650filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—103,219filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—82,265filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—82,000filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—65,900filing
11 Jun 2024filed 11 Jun 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code D—69,100filing
11 Jun 2024filed 11 Jun 2024Deciphera PharmaceuticalsSEC FORM 4 Code A—34,157filing
11 Jun 2024filed 11 Jun 2024Deciphera PharmaceuticalsSEC FORM 4 Code D—72,029filing
11 Jun 2024filed 11 Jun 2024Deciphera PharmaceuticalsSEC FORM 4 Code U—42,478filing
16 Feb 2024filed 20 Feb 2024Deciphera PharmaceuticalsSEC FORM 4 Sold$47K3,010 at $15.62filing
15 Feb 2024filed 20 Feb 2024Deciphera Pharmaceuticalsoption or derivativeSEC FORM 4 Code A—69,100 at $0.00filing
15 Feb 2024filed 20 Feb 2024Deciphera PharmaceuticalsSEC FORM 4 Code A—17,275 at $0.00filing
16 Jan 2024filed 18 Jan 2024Deciphera PharmaceuticalsSEC FORM 4 Sold$35K2,435 at $14.47filing
13 Dec 2023filed 14 Dec 2023Deciphera PharmaceuticalsSEC FORM 4 Sold$43K2,792 at $15.37filing

Sectors

Health Care1
Not placed28

Buys in green, sells in red, by the company’s sector.

Related people

Ian MortimerPresident & CEO · President & CEO at Xenon Pharmaceuticals, filing Form 4 there in the last year
Dawn SvoronosDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year
Christopher John KenneyChief Medical Officer · Chief Medical Officer at Xenon Pharmaceuticals, filing Form 4 there in the last year
Steven GannonDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year
Gillian CannonDirector · Director at Xenon Pharmaceuticals, filing Form 4 there in the last year